Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Gilead posts ARTISTRY-2 results; registers GS-1179 herpes trial and ARTISTRY-3 HIV studyNov 5Weekly roundup, 4 itemsbictegravirbictegravir/lenacapavirUpdated
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.